Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-04-03 16:03:55 -

GLOSTRUP, Denmark, April 3, 2013 - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, recently received clearance from the
U.S. Food and Drug Administration to sell FLEX Monoclonal Rabbit Anti-Human
Estrogen Receptor alpha, Clone EP1 in the United States.  The clone has been
available in Europe for some time and has enjoyed widespread acceptance.

"We are very pleased to now be able to supply our customers in the United States
with this high-quality antibody for estrogen receptor testing on Dako's
Autostainer Link 48," said Karen Balstrup, global product manager, IHC Reagents,
at Dako.

Research has shown that tumor growth is dependent on the presence of estrogen,
progesterone or both in most breast cancers. Estrogen receptor (ER) status in
breast carcinomas is a validated prognostic and predictive factor for 
managing a patient's anti-hormonal therapy.  With this important diagnostic tool from Dako, breast cancer patients can be confident they are receiving the most effective treatment for their particular type of breast cancer. Clone EP1 shows excellent concordance with the existing ER component from Dako's ER/PR pharmDx Kit, with an overall agreement of 97.7 percent, a strong indication that pathologists can rely on the results obtained from using this antibody. "Clone EP1 specifically detects nuclear estrogen receptor without cytoplasmic staining and shows a high degree of concordance (greater than 95 percent) to existing clones," said Sunil S. Badve, M.D., Department of Pathology and Laboratory Medicine, Indiana University. "Compared with other established ER antibody assays this new clone is a highly sensitive and specific antibody." The Monoclonal Rabbit Anti-Human ER alpha, Clone EP1 was created by Epitomics Inc., using Epitomics' proprietary rabbit monoclonal antibody technology covered under Patent Nos. 5,675,063 and 7,402,409. Dako and Epitomics entered into a collaboration in 2011 which allows the companies to unite competencies to provide the anatomic pathology market with state-of-the-art antibodies. About Dako - An Agilent Technologies Company Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at www.dako.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com. CONTACTS Dako Products: Victoria Wadsworth-Hansen Dako Denmark A/S +45 29336980 Dako Corporate: Maia Fredtoft Søchting Dako Denmark A/S +45 25461083 Press Release pdf: hugin.info/136715/R/1689765/554670.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Dako Denmark A/S via Thomson Reuters ONE [HUG#1689765]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com